The Consumer Takeover
What Global and Indian Pharma Must Learn from China’s Market
The global pharmaceutical industry is watching a revolution, and it’s happening in China. The traditional model where companies focus only on doctors and hospitals is being replaced by a new, consumer-driven game. This shift is so significant that it offers crucial lessons for every major player, from global corporations to Indian generic manufacturers.
A few key forces are powering this change. Chinese patients are now “consumers.” They use the internet to research symptoms, compare medicines online, and read reviews before seeing a doctor. E-commerce platforms like JD Health and Tmall Health have become major pharmacies, allowing people to buy healthcare products as easily as they buy clothes.
New government policies, especially Volume-Based Procurement (VBP), have forced down drug prices within hospitals. To maintain growth, pharmaceutical companies must now look beyond hospitals and sell directly to consumers through retail and online channels.
Patients are more informed and empowered than ever. They want a say in their treatment and are building loyalty to brands they trust, not just to what the doctor orders. The power is shifting from the doctor’s prescription pad to the consumer’s smartphone.
For large international companies, China is a preview of what’s coming to the rest of the world. Trends like digital health, cost pressures, and patient empowerment are appearing everywhere. Global pharma can use China as a blueprint to prepare for this shift in their own markets and create a new playbook for growth. maybe Indian pharma will wake up then, although I doubt it (look at the wave of innovation in China).
As governments in the West also push for lower drug prices, the high-profit hospital model will shrink. China shows that the future lies in building direct relationships with consumers through retail pharmacies and online channels. Chinese companies are mastering digital marketing (while we ask if doctors have the time), and creating “all-in-one” health apps for patients. Global pharma must learn these new skills to build a brand and engage patients online, or risk losing ground to more agile local competitors.
For Indian companies, which are famous as the “Pharmacy of the World” for their generic drugs, China’s change is a major opportunity and a warning. Indian firms have found it difficult to break into the Chinese hospital system. The rise of e-commerce provides a direct channel to 1.4 billion consumers, allowing them to bypass traditional barriers and sell their products online.
Indian pharma is mostly a B2B industry (CMOs), selling unbranded products to other companies. The Chinese model teaches them how to build their own brand names directly with consumers. This builds loyalty and allows them to earn higher profits, not just compete on low price. India is also seeing the rise of online pharmacies like Tata 1mg and PharmEasy. By learning from China’s experience, Indian companies can prepare for the same consumer shift in their own backyard.
The patient is now a consumer. The future of pharma belongs to companies that can do more than just develop effective drugs. They must also learn to market them, build trust, and engage directly with the people who use them.
For global pharma, this is a call to adapt commercial models. For Indian pharma, it’s a roadmap to become global consumer brands. Those who pay attention and learn from China’s experiment will survive into the next era in medicine.